'Best Technology 2009' Award

RNS Number : 9985A

Immupharma PLC

19 October 2009

 



FOR IMMEDIATE RELEASE

19 OCTOBER 2009

 

ImmuPharma PLC

("ImmuPharma")

ImmuPharma wins 'Best Technology 2009' Award at the AIM Awards

ImmuPharma PLC (LSE: IMM) the specialist discovery and development pharmaceutical company, has won the Best Technology Award at the AIM Awards 2009, organized by the London Stock Exchange. 

The Award, announced at the AIM Awards Dinner in London on 15 October 2009, is presented to the company which reflects the innovation and entrepreneurial skills that are considered the cornerstone of the AIM culture.

Commenting on the award, Richard Warr, Chairman of ImmuPharma said: "ImmuPharma is honoured to receive the Best Technology Award at the 2009 AIM Awards Dinner. It is a prestigious award and I should like to thank the AIM community for recognising the innovation and entrepreneurial skills that have driven ImmuPharma forward over the last few years. This Award builds on our success at the European Mediscience Awards in June 2009 where ImmuPharma was awarded the Breakthrough of the Year Award. For ImmuPharma the journey is very much beginning and to have received such public recognition over the past year is particularly rewarding."

- Ends -

For further information please contact: 

ImmuPharma PLC	[phone]
Dimitri Dimitriou, Chief Executive Officer  Richard Warr, Chairman
Buchanan Communications	[phone]
Lisa Baderoon
Panmure Gordon & Co                      Andrew Burnett Rakesh Sharma	[phone]
Noble & Company Limited	[phone]
James Bromhead Sam Reynolds

Notes to Editors

About ImmuPharma PLC

ImmuPharma is a drug discovery and development group with its key operations in London and subsidiaries in Mulhouse, France and Basle, Switzerland. The Company aims to develop novel drugs to treat serious medical conditions for which there is a high unmet need. It has five drugs in development to treat 1) Lupus, 2) Cancer, 3) Severe Pain, 4) Highly resistant infections like MRSA and 5) Inflammatory and Allergic disorders. 

Its lead candidate for the treatment of Lupus, LupuzorTM, a chronic, life-threatening autoimmune disease, was licensed to Cephalon, Inc in a transaction worth up to $500m in milestone payments in addition to significant royalties. $45m in cash has been received to date - $15m in Q4 2008 and $30m post year end in Q1 2009

The company also has a strong proprietary and collaborative drug development pipeline.

 

END

 

 

NRAMLBLTMMTBMPL